Scholarlink

<p>Sugen kinase 495 (<i>Sgk495</i>), also known as Serine/Threonine Kinase 40 (<i>STK40</i>), is a pseudokinase previously implicated in T cell differentiation via regulation of Foxo transcription factors. However, its function and mechanism in lung squamous cell carcinoma (LUSC) remain unclear. Here, we report that <i>Sgk495</i> is highly expressed in LUSC tissues and correlates with shorter disease-free survival in patients. Knockdown of <i>Sgk495</i> significantly inhibited the proliferation, migration, and invasion of LUSC cells. Mechanistically, <i>Sgk495</i> facilitates the binding of the E3 ubiquitin ligase <i>COP1</i> to <i>Foxo1</i>, enhancing K48-linked polyubiquitination and subsequent proteasomal degradation of <i>Foxo1</i>. This process alleviates the tumor-suppressive effects of <i>Foxo1</i>, thereby promoting the oncogenic capabilities of LUSC cells in vivo. Our findings identify <i>Sgk495</i> as an oncogene in LUSC acting through the <i>COP1</i>/<i>Foxo1</i> axis, revealing a potential therapeutic target for this malignancy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sugen kinase 495 promotes the proliferation, migration and invasion of lung squamous cell carcinoma cells by targeting Foxo1 transcription factor

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月18日

查看全文
  • Yuanmei Lou,
  • Jun Chen,
  • Yangpeng Tang,
  • Yingying Zhou,
  • Chaowu Liu,
  • Lin Mi,
  • Hanbo Le,
  • Zhijun Chen

摘要

Sugen kinase 495 (Sgk495), also known as Serine/Threonine Kinase 40 (STK40), is a pseudokinase previously implicated in T cell differentiation via regulation of Foxo transcription factors. However, its function and mechanism in lung squamous cell carcinoma (LUSC) remain unclear. Here, we report that Sgk495 is highly expressed in LUSC tissues and correlates with shorter disease-free survival in patients. Knockdown of Sgk495 significantly inhibited the proliferation, migration, and invasion of LUSC cells. Mechanistically, Sgk495 facilitates the binding of the E3 ubiquitin ligase COP1 to Foxo1, enhancing K48-linked polyubiquitination and subsequent proteasomal degradation of Foxo1. This process alleviates the tumor-suppressive effects of Foxo1, thereby promoting the oncogenic capabilities of LUSC cells in vivo. Our findings identify Sgk495 as an oncogene in LUSC acting through the COP1/Foxo1 axis, revealing a potential therapeutic target for this malignancy.